Generic Injectable Market to Benefit from Increasing Patent Expiry of Blockbuster Injectable Drugs, Set for Double-digit CAGR through 2029
The generic pharmaceutical industry is witnessing a significant surge in the number of FDA-approved new generic entities every year, owing to numerous factors such as growing number of patent expiries, government policies and demographics, new higher-value opportunities in complex generics and biosimilars, pace of abbreviated new drug application (ANDA) approvals by the FDA, and introduction of cost-effective injectables through mergers and consolidation in the generic injectable market.
Primary factors for the growth of the generic injectable market include nature and degree of portfolio differentiation, and scale and age of manufacturing facilities. Growing drug shortages and formation of task forces to overcome these challenges, growing CAPEX index in various countries, and supply of life-saving essential injectable drugs, specifically in emerging and developing countries, are driving market growth.
The global generic injectable market was estimated to be valued at around US$ 64 Bn in 2018, with the market expected to exhibit a CAGR of nearly 12% during the forecast period (2019-2029).
Download Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-6051
“Demand from emerging markets, improvements in product formulations, loss of exclusivity (LOE), and growth strategies based on acquisitions and mergers are projected to offer key growth opportunities for the generic injectable market.”
Key Takeaways of Generic Injectable Market Study
- Uninterrupted focus on areas of strength while striving for higher complexity portfolios and pipelines is the core strategy outlined for success in the injectable pharmaceutical space.
- High upfront capital investments as well as maintenance of CAPEX to maintain USFDA cGMP-compliant generic sterile injectable plants to increase gross margins.
- The sale of biologics such as monoclonal antibodies, vaccines, etc., in the global generic injectable market, has increased significantly, owing to vast benefits over branded drug entities and availability of cost-efficient alternatives.
- Increasing government budget deficits and higher government debt burdens have resulted in increasing focus on reducing healthcare spending/pricing.
- Drastic reduction in development time and growing consolidation efforts by manufacturers are expected to boost the demand for small molecule generic injectables and large molecule generic injectables in the healthcare industry.
- Monoclonal antibodies with comparatively higher biosimilar capabilities and price advantage over branded injectables are expected to generate significant revenue.
Strategic Acquisition by Key Players to Widen Regional Presence
Leading players in the generic injectable market such as Pfizer Inc., Hospira Inc., Hikma, and Mylan are concentrating on business expansions by mergers and distribution agreements, and capturing the untapped potential of the generic injectable market.
- In 2015, Pfizer Inc. acquired Hospira Inc., the largest generic injectable manufacturer for US$ 17 billion. With this acquisition, Pfizer Inc. entered deep into the generic injectable market and leveraged the core assets of Hospira in generic injectables. This acquisition further strengthened Pfizer’s hold of the generic injectable business.
- The significant acquisition led by Hikma Pharmaceuticals Inc. in 2014 for the U.S. generic injectable assets of Boehringer Ingelheim, Hikma gained a portfolio of 88 generics in the specialized and niche segments of the market, including respiratory, oncology, controlled, and extended release substances.
- Acquisition of Par Pharma Group by Endo International PLC in 2015.
Additionally, recent acquisitions were driven by the need to acquire product portfolios, development pipelines, and manufacturing capabilities of existing injectable players, to consolidate market share and accelerate entry into the promising U.S. generic injectable market.
Download Market Shares of Leading Players@ https://www.futuremarketinsights.com/ask-question/rep-gb-6051
More Valuable Insights on Generic injectable Market
Future Market Insights brings a comprehensive research report on forecasted revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the segments from 2014 to 2029. The global generic injectable market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
The study provides compelling insights on the generic injectable market on the basis of product (monoclonal antibodies, immunoglobulin, cytokines, insulin, peptide hormones, blood factors, peptide antibiotics, vaccines, small molecule antibiotics, chemotherapy agents, and others), molecule type (small molecules and large molecules), application (oncology, infectious diseases, diabetes, blood disorders, hormonal disorders, musculoskeletal disorders, CNS diseases, pain management, and cardiovascular diseases), route of administration (intravenous (IV), intramuscular (IM), and subcutaneous (SC)), and distribution channel (hospital pharmacies, retail pharmacies, drug stores, and online pharmacies), across seven major regions.
Explore Future Market Insights’ detailed coverage on,
Home Sleep Screening Devices Market– This research report provides an exhaustive range of insights which identify revenue sectors, essential strategies, and major growth opportunities, associated with home sleep screening devices.
Amniotic Membrane Market– This report includes a detailed analysis on competitive scenarios, and essential information on major players in the amniotic membrane market.
Allergy Diagnostics Market– This write up encompasses detailed secondary research, which is used to estimate key industry players, overall size of the allergy diagnostics market, and relevant industry associations.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: firstname.lastname@example.org
For Media Enquiries: email@example.com